Novo Nordisk (NVO.US) weight loss drug patent will expire in multiple places next year, Indian bulk drug manufacturers rush into the $94 billion market.

Zh tng cijng APP hu xn, shnchn yunlio yo (Active Pharmaceutical Ingredients, jinchng APIs) de ynd qy zhn jj chubi jhu gngyn yny shngchn nu h nud (NVO.US) jinzhn yow fnzhyo gunjin yunlio de gngun wnt. Zhxi jinzhn yow jin y mng nin zi duge zhyo shchn sh huqun boh. According to the China Fortune APP, Indian companies producing active pharmaceutical ingredients (APIs) are actively preparing plans to supply key ingredients for generic versions of the weight loss drug Novo Nordisk (NVO.US). These weight loss drugs will lose patent protection in multiple major markets next year.